IceCure signs exclusive ProSense distribution deal with Scovas Medical in Netherlands
ICCM•THERMAC trial support and prior data
The partnership aligns with the Netherlands-based THERMAC trial, which is now in Phase III with cryoablation selected for continued evaluation.
Prior THERMAC data cited a 94% complete ablation rate, 0% complication rate, and 100% treatment tolerance without general anesthesia.
Exclusive distribution agreement in the Netherlands
IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for ProSense cryoablation systems in the Netherlands.
The deal covers breast cancer treatment and interventional oncology, supporting broader commercialization in a key European market.
The initial term includes an option to negotiate a longer-term agreement, subject to mutual consent.
